Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 19 citing articles:

Projections up to 2100 and a budget optimisation strategy towards cervical cancer elimination in China: a modelling study
Changfa Xia, Shangying Hu, Xiaoqian Xu, et al.
The Lancet Public Health (2019) Vol. 4, Iss. 9, pp. e462-e472
Open Access | Times Cited: 63
Effectiveness and cost-effectiveness of eliminating cervical cancer through a tailored optimal pathway: a modeling study
Changfa Xia, Xiaoqian Xu, Xuelian Zhao, et al.
BMC Medicine (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 34
Influences of HPV disease perceptions, vaccine accessibility, and information exposure on social media on HPV vaccination uptake among 11,678 mothers with daughters aged 9–17 years in China: a cross-sectional study
Zian Lin, Siyu Chen, Lixian Su, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 4
Cervical cancer screening by cotesting method for Vietnamese women 25–55 years old: a cost-effectiveness analysis
Hien Bui, Van Nu Hanh Pham, Thang Hong Vu
BMJ Open (2025) Vol. 15, Iss. 1, pp. e082145-e082145
Open Access
Projected Time for the Elimination of Cervical Cancer Under Various Intervention Scenarios: Age-Period-Cohort Macrosimulation Study
Yi‐Chu Chen, Yun‐Yuan Chen, Shih‐Yung Su, et al.
JMIR Public Health and Surveillance (2024) Vol. 10, pp. e46360-e46360
Open Access | Times Cited: 3
Informing HPV vaccine pricing for government-funded vaccination in mainland China: a modelling study
Tingting You, Xuelian Zhao, Chenghao Pan, et al.
The Lancet Regional Health - Western Pacific (2024) Vol. 52, pp. 101209-101209
Open Access | Times Cited: 2
Modeling the Health Impact and Cost-Effectiveness of a Combined Schoolgirl HPV Vaccination and Cervical Cancer Screening Program in Guangdong Province, China
Yating Huang, Dantao Zhang, Lihua Yin, et al.
Children (2024) Vol. 11, Iss. 1, pp. 103-103
Open Access | Times Cited: 1
Modeling the epidemiological impact and cost-effectiveness of a combined schoolgirl HPV vaccination and cervical cancer screening program among Chinese women
Xiaomeng Ma, Katherine Harripersaud, M. Kumi Smith, et al.
Human Vaccines & Immunotherapeutics (2020) Vol. 17, Iss. 4, pp. 1073-1082
Open Access | Times Cited: 12
Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore
Lee Cheng Phua, Cheuk‐Wai Choi, Joseph T. Wu, et al.
Vaccine (2021) Vol. 39, Iss. 16, pp. 2255-2263
Closed Access | Times Cited: 11
Maximizing the cost-effectiveness of cervical screening in the context of routine HPV vaccination by optimizing screening strategies with respect to vaccine uptake: a modeling analysis
Cheuk‐Wai Choi, Kathy Leung, Karen K. L. Chan, et al.
BMC Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 4
Cost-effectiveness of human papillomavirus vaccine in China: a systematic review of modelling studies
Wenchuan Shi, Xiaoli Cheng, Haitao Wang, et al.
BMJ Open (2021) Vol. 11, Iss. 12, pp. e052682-e052682
Open Access | Times Cited: 10
The cost-effectiveness of prostate health index for prostate cancer detection in Chinese men
Jeremy Yuen‐Chun Teoh, Chi-Ho Leung, Maggie Haitian Wang, et al.
Prostate Cancer and Prostatic Diseases (2020) Vol. 23, Iss. 4, pp. 615-621
Closed Access | Times Cited: 8
The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong
Tak Hong Cheung, Sally Shuk Yee Cheng, Danny Hsu, et al.
Cost Effectiveness and Resource Allocation (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 8
Status and epidemiological characteristics of high-risk human papillomavirus infection in multiple centers in Shenyang
Di Yang, Jing Zhang, Xiaoli Cui, et al.
Frontiers in Microbiology (2022) Vol. 13
Open Access | Times Cited: 4
Accounting for Adverse Events Following Immunization in Economic Evaluation: Systematic Review of Economic Evaluations of Pediatric Vaccines Against Pneumococcus, Rotavirus, Human Papillomavirus, Meningococcus and Measles-Mumps-Rubella-Varicella
Kris Doggen, Albert Jan van Hoek, Jeroen Luyten
PharmacoEconomics (2023) Vol. 41, Iss. 5, pp. 481-497
Closed Access | Times Cited: 2
Cost–Benefit Analysis of Human Papillomavirus Vaccine in Iran
Nasrin Sargazi, Amirhossein Takian, Rajabali Daroudi, et al.
Journal of Prevention (2022) Vol. 43, Iss. 6, pp. 841-857
Open Access | Times Cited: 3
Public health impact of 2-, 4-, and 9-valent HPV vaccination in females on cervical and noncervical diseases in men and women under different coverage scenarios in China: A simulation study
I. Diakité, J. Kyle, Sujian Situ, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 2
Open Access | Times Cited: 1
HPV vaccination and sexual behaviour in healthcare seeking young women in Luxembourg
Camille Soudeyns, Niko Speybroeck, Marc Brisson, et al.
PeerJ (2020) Vol. 8, pp. e8516-e8516
Open Access | Times Cited: 3
Projected Time for the Elimination of Cervical Cancer Under Various Intervention Scenarios: Age-Period-Cohort Macrosimulation Study (Preprint)
Yi‐Chu Chen, Yun‐Yuan Chen, Shih‐Yung Su, et al.
(2023)
Open Access
Page 1

Scroll to top